Table 2 Final predictive probabilities of success of ganitumab and metformin with paclitaxel followed by anthracyclines in HER2− biomarker signatures. The combination failed to graduate in any of the three signatures.
From: Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Biomarker signature | Estimated rate of pathologic complete response % (95% Probability Interval) | Prob. superior to control, % | Predictive prob. of success in phase III Trial, % | |
|---|---|---|---|---|
Ganitumab n = 106 | Control n = 128 | |||
All HER2− | 22 (13–31) | 16 (10–23) | 89 | 33 |
HR+/HER2− | 14 (4–24) | 12 (4–19) | 61 | 21 |
HR−/HER2− | 32 (17–46) | 21 (11–32) | 91 | 51 |
